Drug Profile
AZD 5122
Alternative Names: AZD5122Latest Information Update: 12 Aug 2010
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class
- Mechanism of Action Interleukin 8B receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Chronic obstructive pulmonary disease
Most Recent Events
- 29 Jul 2010 Discontinued - Phase-I for Chronic obstructive pulmonary disease in United Kingdom (IV)
- 29 Jul 2010 Discontinued - Phase-I for Chronic obstructive pulmonary disease in United Kingdom (PO)
- 21 Sep 2009 Phase-I clinical trials in Chronic obstructive pulmonary disease in United Kingdom (IV)